Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04823624 · ClinicalTrials.gov registry record · Phase 2
MBG453 in Lower Risk MDS
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT04823624: Clinical Trial Phase 2 study, sponsored by Massachusetts General Hospital.
NCT04823624 is a Phase 2 study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04823624, a Phase 2 study, was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
This research study is assessing the efficacy of MBG-453, a humanized monoclonal antibody, in treating myelodysplastic syndromes (MDS). The name of the study drug involved in this study is MBG453.
Interventions
- DRUG MBG453
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2022-01-27 |
| Est. Completion | 2025-11-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04823624
The ClinicalTrials.gov registry entry for NCT04823624 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MBG453 is the first listed.
NCT04823624 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04823624 about?
NCT04823624 is a clinical study titled "MBG453 in Lower Risk MDS". This research study is assessing the efficacy of MBG-453, a humanized monoclonal antibody, in treating myelodysplastic syndromes (MDS). The name of the study drug involved in this study is MBG453.
What is the current status of trial NCT04823624?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2022-01-27. Estimated completion is 2025-11-01.
What interventions are being tested in trial NCT04823624?
The interventions under investigation include: MBG453 (DRUG).
Who is sponsoring clinical trial NCT04823624?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.